changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
“You have liver cancer”, can be a life altering experience and can start a cascade of emotions. By spending time researching treatment options for either yourself or a loved one, you are ensuring you will be receiving the best care available today based on individual needs.
TheraSphere®, is a low toxicity, targeted liver cancer therapy that consists of millions of tiny glass beads containing radioactive yttrium-90. The glass beads - about the third of the width of a human hair – are delivered directly to the liver tumors.
This patient website includes details about what to expect from typical TheraSphere® treatment activities and possible side effects. It also contains helpful information such a glossary and patient resources.<br />
Ask your doctor if TheraSphere® is right for you.
Clinical Trials with TheraSphere Yttrium-90 Glass Microspheres.
Radioembolization treatment for primary ...
BTG announces National Reimbursement for...
OPTALYSE PE Results Presented at Society...
Healthcare Player BTG on lookout for acq...
NICE highlights potential role of TheraS...